KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Research & Development (2016 - 2026)

Teva Pharmaceutical Industries filings provide 18 years of Research & Development readings, the most recent being $222.0 million for Q1 2026.

  • On a quarterly basis, Research & Development fell 10.12% to $222.0 million in Q1 2026 year-over-year; TTM through Mar 2026 was $989.0 million, a 1.4% decrease, with the full-year FY2025 number at $1.0 billion, up 1.5% from a year prior.
  • Research & Development hit $222.0 million in Q1 2026 for Teva Pharmaceutical Industries, down from $267.0 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $269.0 million in Q2 2024 to a low of $175.0 million in Q3 2022.
  • Median Research & Development over the past 5 years was $240.0 million (2023), compared with a mean of $236.8 million.
  • Biggest five-year swings in Research & Development: decreased 21.17% in 2022 and later skyrocketed 44.57% in 2023.
  • Teva Pharmaceutical Industries' Research & Development stood at $210.0 million in 2022, then rose by 8.1% to $227.0 million in 2023, then grew by 8.81% to $247.0 million in 2024, then rose by 8.1% to $267.0 million in 2025, then fell by 16.85% to $222.0 million in 2026.
  • The last three reported values for Research & Development were $222.0 million (Q1 2026), $267.0 million (Q4 2025), and $256.0 million (Q3 2025) per Business Quant data.